Terapia Génica en Enfermedad de Parkinson
PARKBA SAL
Julen
Oyarzabal Santamarina
Investigador hasta 2018
Publicaciones en las que colabora con Julen Oyarzabal Santamarina (6)
2019
-
Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910
2017
-
Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors
Frontiers in Pharmacology, Vol. 8, Núm. OCT
2016
-
Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels
Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415
-
Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay
Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 3, pp. 580-587
2014
-
Phosphodiesterase inhibition in cognitive decline
Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573
2013
-
Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD
Neuropharmacology, Vol. 64, pp. 114-123